Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) AI Stock Analysis

• Market Cap: HK$10.60B
• Dividend Yield: 4.26%
• Average Volume (3M): 211.55K
• Price to Earnings (P/E): 14.2
• Beta (1Y): 0.88
• Revenue Growth: -8.54%
• EPS Growth: -9.46%
• Country: HK
• Employees: 2,156
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.45
• Shares Outstanding: 38,529,240
• 10 Day Avg. Volume: 238,704
• 30 Day Avg. Volume: 211,551
• PEG Ratio: -0.53
• Price to Book (P/B): 1.05
• Price to Sales (P/S): 2.18
• P/FCF Ratio: 20.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: HK$27.00 ▲(8.43% Upside)

Shanghai Haohai Biological Technology Co., Ltd. receives a score of 64, primarily influenced by its stable financial performance and attractive valuation. The company's strong profitability margins and low leverage contribute positively, while the low P/E ratio and high dividend yield suggest potential undervaluation. However, the stock's technical indicators are bearish, indicating a downtrend and oversold conditions, which weigh negatively on the overall score.

Positive Factors

Strong Profitability Margins

High profitability margins indicate effective cost management and pricing power, supporting long-term financial stability and competitive positioning.

Low Leverage

Low leverage reduces financial risk and interest obligations, providing the company with greater flexibility to invest in growth opportunities.

Positive Cash Flow Trend

Growing free cash flow enhances the company's ability to fund operations, invest in R&D, and return capital to shareholders, supporting sustainable growth.

Negative Factors

Declining Revenue

Declining revenue can signal weakening demand or competitive pressures, which may impact long-term growth prospects and market share.

Negative EBIT Margin

A negative EBIT margin suggests operational inefficiencies or cost pressures, which could hinder profitability and require strategic adjustments.

Revenue Growth Challenges

Ongoing revenue growth challenges may limit the company's ability to scale operations and invest in new market opportunities, affecting long-term competitiveness.

Shanghai Haohai Biological Technology Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Shanghai Haohai Biological Technology Co., Ltd. is a leading biotechnology company based in Shanghai, China, specializing in the research, development, production, and commercialization of innovative medical devices and biopharmaceuticals. The company primarily operates in the fields of surgical sutures, wound care products, and regenerative medicine, focusing on enhancing patient outcomes through advanced technology and high-quality products. Haohai is committed to innovation and is dedicated to providing superior healthcare solutions to both domestic and international markets.

How the Company Makes Money

Shanghai Haohai Biological Technology Co., Ltd. generates revenue through multiple key streams, including the sales of its core products such as surgical sutures and wound care solutions, which are distributed to hospitals and healthcare providers. The company also engages in research partnerships with medical institutions and universities to develop new biopharmaceutical products, which can lead to licensing agreements and collaborative projects that provide additional income. Furthermore, Haohai benefits from government grants and subsidies aimed at promoting biotechnology innovation, contributing to its overall financial stability and growth. The company’s strategic focus on expanding its market presence internationally, coupled with ongoing investments in R&D, positions it well for sustained revenue generation.

Shanghai Haohai Biological Technology Co., Ltd. Class H Financial Statement Overview

Summary

Shanghai Haohai Biological Technology Co., Ltd. demonstrates strong revenue growth and profitability, supported by a robust balance sheet with low leverage. However, missing data in 2024 for key metrics could pose future analytical challenges. The company should focus on maintaining operational efficiency and improving cash flow visibility.

Income Statement

The company's revenue has shown consistent growth, with a notable increase from 2022 to 2023. The gross profit margin remains strong, indicating efficient cost management. Net income has also increased, demonstrating profitability. However, there is a slight decline in EBITDA margin, which could indicate rising operational costs.

Balance Sheet

The company has a strong equity position, with liabilities being significantly lower than stockholders' equity, leading to a healthy debt-to-equity ratio. However, the absence of total assets in 2024 data makes it challenging to calculate key ratios like equity ratio and return on equity (ROE) for the latest year.

Cash Flow

Operating cash flow showed substantial growth in 2023 but is missing for 2024, which raises concerns about cash management. The free cash flow turned positive in 2023, showing improved cash efficiency. However, the lack of data for 2024 limits further analysis.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.57B	2.68B	2.63B	2.10B	1.75B	1.32B
Gross Profit	1.36B	1.87B	1.85B	1.45B	1.26B	990.42M
EBITDA	604.94M	549.05M	713.41M	447.55M	550.45M	394.80M
Net Income	392.58M	420.45M	416.12M	180.47M	352.23M	230.07M
Balance Sheet
Total Assets	7.78B	7.12B	7.11B	6.89B	6.95B	6.30B
Cash, Cash Equivalents and Short-Term Investments	2.84B	2.76B	2.75B	2.56B	2.91B	3.11B
Total Debt	451.27M	448.43M	407.95M	118.26M	105.51M	108.08M
Total Liabilities	1.35B	1.20B	1.09B	990.02M	890.07M	564.46M
Stockholders Equity	6.14B	5.58B	5.65B	5.51B	5.71B	5.49B
Cash Flow
Free Cash Flow	419.48M	283.08M	367.22M	-85.85M	70.19M	66.21M
Operating Cash Flow	644.26M	648.57M	634.45M	231.30M	342.29M	262.07M
Investing Cash Flow	-237.17M	282.28M	-376.65M	-681.82M	-148.09M	316.92M
Financing Cash Flow	-561.75M	-390.35M	-257.73M	-288.35M	-231.25M	-190.06M

Shanghai Haohai Biological Technology Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 24.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6826, the sentiment is Negative. The current price of 24.9 is below the 20-day moving average (MA) of 26.80, below the 50-day MA of 27.08, and below the 200-day MA of 26.34, indicating a bearish trend. The MACD of -0.54 indicates Positive momentum. The RSI at 36.02 is Neutral, neither overbought nor oversold. The STOCH value of 25.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6826.

Shanghai Haohai Biological Technology Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2315	66 Neutral	HK$11.18B	78.16	16.13%	―	48.38%	―
6826	64 Neutral	HK$10.60B	14.18	6.69%	4.26%	-8.54%	-9.46%
1672	54 Neutral	HK$12.99B	-45.61	-12.74%	―	-76.58%	-4.90%
2171	53 Neutral	HK$8.67B	-15.09	-42.46%	―	1219.19%	25.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2162	41 Neutral	HK$15.58B	―	-8.79%	―	964.40%	65.90%
2157	40 Underperform	HK$10.09B	-48.22	-21.42%	―	240.05%	-140.09%

Shanghai Haohai Biological Technology Co., Ltd. Class H Corporate Events

Shanghai Haohai Acquires Full Ownership of Subsidiary

Shanghai Haohai Biological Technology Co., Ltd. announced the acquisition of the remaining 20% equity interest in a previously non-wholly owned subsidiary, making it a fully owned subsidiary. This transaction, valued at RMB74,000,000, consolidates the company’s control over the subsidiary, potentially enhancing its operational efficiency and financial performance. The acquisition is classified as a connected transaction under Hong Kong’s Listing Rules, but it is exempt from the requirement for independent shareholders’ approval due to the applicable percentage ratios.

Shanghai Haohai Biological Technology Releases 2025 Q3 Financial Report

Shanghai Haohai Biological Technology Co., Ltd. has released its unaudited third quarterly report for 2025, detailing financial results for the three and nine months ending September 30, 2025. The report, prepared in accordance with Chinese Accounting Standards, highlights the company’s financial performance and is intended to inform shareholders and potential investors about the company’s current financial status. The board emphasizes the importance of understanding the investment risks associated with the company’s financial data.

Shanghai Haohai Biological Technology Schedules Board Meeting for Q3 Results

Shanghai Haohai Biological Technology Co., Ltd. has announced a board meeting scheduled for October 24, 2025, to consider and approve the company’s third quarterly results for the period ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.